Photo from wikipedia
Anticoagulation therapy with the vitamin K antagonist (VKA) warfarin has been demonstrated to reduce thromboembolic risk after electrical cardioversion (ECV). However, data concerning ECV with non‐VKA oral anticoagulants (NOACs) is… Click to show full abstract
Anticoagulation therapy with the vitamin K antagonist (VKA) warfarin has been demonstrated to reduce thromboembolic risk after electrical cardioversion (ECV). However, data concerning ECV with non‐VKA oral anticoagulants (NOACs) is limited. The objective of this study was to determine the efficacy and safety of NOACs in patients undergoing ECV in a real‐world clinical practice at a single center in Japan.
Keywords:
single center;
clinical practice;
oral anticoagulants;
practice single;
vitamin antagonist;
cardioversion
Journal Title: Journal of Arrhythmia
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Arrhythmia
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!